Prothena Corp Public Ltd Co (PRTA) · Oct 29, 2026 · Agreement terminated
$617.5M milestones lost — Up to $617.5M in development, regulatory, and sales milestones plus royalties
Prothena’s PRX019 termination ends a partnered neurodegeneration program after Phase 1, eliminating up to $617.5M in future milestones and royalties.
Prothena is a late-stage neurodegeneration biotech whose partnered pipeline includes Roche’s Phase 3 prasinezumab, Novo Nordisk’s Phase 3 coramitug, and Bristol Myers Squibb’s Phase 2 moponetug; PRX019 was the earlier-stage, undisclosed-target addition to that portfolio.
BMS has stopped PRX019 before it became a meaningful pipeline asset. Bristol Myers Squibb decided not to advance the program, and the license agreement will terminate on January 28, 2027. 〔0〕 〔1〕
The economic hit is the loss of the program’s long-term upside, not a new near-term cash charge disclosed here. Prothena received the $80 million upfront payment in 2024, but it will no longer receive PRX019’s potential development, regulatory, or sales milestones of up to $617.5 million, or the associated royalties. 〔2〕
The decision is more negative because it came despite a clean Phase 1 profile, while the reason for stopping remains unclear. The trial met Prothena’s stated safety, immunogenicity, pharmacokinetic, and pharmacodynamic objectives, but those results were not enough for BMS to commit to further development. The filing does not identify whether the issue was efficacy confidence, target validation, commercial prioritization, or another strategic consideration. 〔3〕
The broader BMS relationship is damaged but not broken. BMS continues developing moponetug, Prothena’s tau-targeting Alzheimer’s antibody, in the Phase 2 TargetTau-1 trial; that is now the key remaining BMS-linked clinical asset to watch. Prothena says BMS has paid $135 million for moponetug and that up to $562.5 million in additional milestones remain available. 〔4〕
Bottom line: This removes a fully licensed clinical program and a substantial pool of contingent milestone and royalty value from Prothena’s pipeline. The remaining BMS relationship still matters, but the company now has less partnered breadth and more dependence on moponetug and its other collaborations.
TargetTau-1 Phase 2 completion, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!